Briumvi (Ublituximab-xiiy)
Briumvi (Ublituximab-xiiy)
- Medicine Name: Briumvi
- API: Ublituximab-xiiy
- Dosage Form & Strength: Injection: 150 mg/6 mL (25 mg/mL) in a single-dose vial
- Manufactured By: TG Therapeutics, Inc.
- Briumvi 150 mg/6 mL injection can cause infusion reactions, which can include chills, headache, pyrexia, influenzalike illness, nausea, tachycardia, throat irritation, anaphylactic reaction, and erythema. Management recommendations for reactions depend on the nature and seriousness of the reaction. Permanently stop therapy if a critical or disabling infusion reaction occurs.
- Severe, including deadly and fatal infections may occur. Delay the administration of Briumvi in those with an active infection until the infection is sorted. Avoid vaccination with live-attenuated or live vaccines during treatment and after discontinuation, until B-cell repletion.
- Monitor immunoglobulin levels at the beginning, throughout, and after stopping therapy with Ublituximab-xiiy injections, until B-cell repletion, and mainly when recurrent critical infections are suspected. Consider discontinuing treatment in those with severe opportunistic or recurrent critical infections, and in case prolonged hypogammaglobulinemia requires treatment with IV immunoglobulins.
- Briumvi may be responsible for causing fetal harm. Advise women of reproductive age/potential of the potential risk to a fetus and to use appropriate contraception during treatment and for at least six months after stopping treatment. A pregnancy test is needed in females of reproductive age before each infusion.
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
- A valid prescription from Doctor
- Import permit if applicable
- On availability of Briumvi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
Indian Pharma Network is able to source the ACCRUFER (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What documents are required to import BRIUMVI to India?
BRIUMVI (ublituximab-xiiy) injection can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients ID proof (issued by the government of India)
The order will be confirmed only after the receipt of:
- A valid prescription from Doctor
- Import permit if applicable
BRIUMVI (ublituximab-xiiy injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
- On availability of Briumvi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
- Medicine Price.
- Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
- Ensuring 100% transparency.
IPN (Indian Pharma Network) can facilitate the supply of BRIUMVI (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).
Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Briumvi 150 mg/6 mL (25 mg/mL) price in India.
We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.